U.S. FTC Seeks More Data About Aussie CSL Buy Of Talecris
This article was originally published in PharmAsia News
Executive Summary
The U.S. Federal Trade Commission has requested more information from Australia's CSL about its bid to take over Talecris Biotherapeutics of the United States. CSL, the world's largest maker of plasma products, said such a request was common for mergers that could have U.S. antitrust implications. CSL, which has proposed buying Talecris for $2 billion, said both firms are cooperating with the FTC as it considers the buyout. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.